Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 20, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Sat, March 18, 2023
[ 12:00 AM ] - United States, WOPRAI
Fri, March 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Uy Ear Reiterated (CABA) at Strong Buy and Held Target at $10 on, Mar 17th, 2023
Uy Ear of Mizuho, Reiterated "Cabaletta Bio, Inc." (CABA) at Strong Buy and Held Target at $10 on, Mar 17th, 2023.
Uy has made no other calls on CABA in the last 4 months.
There are 2 other peers that have a rating on CABA. Out of the 2 peers that are also analyzing CABA, 0 agree with Uy's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Uy
- Michael Ulz of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $16 on, Friday, January 27th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $14 on, Tuesday, January 3rd, 2023
